Rise and shine, everyone, the middle of the week is here. You made it this far, so why not forge ahead, yes? As always, we are doing our best with the help of some cups of stimulation — we are quaffing hazelnut this morning — and invite you to join us. After all, a prescription is not required, so go ahead and indulge. Meanwhile, we have assembled the latest menu of tidbits to get you started on another busy day. Hope all goes well and you conquer the world. Cheers …

Former Novartis (NVS) chief executive Joe Jimenez regrets rushing into a $1.2 million, one-year consulting contract with Michael Cohen, but maintained that uncertainty in early 2017 about the incoming Trump administration prompted the drug maker to sign a deal quickly, Reuters reports. “There should have been more due diligence,” Jimenez said. “There was scarcity of asset, right? I mean, there were very few people who knew the people that were being placed in a lot of jobs.” He said it was a mistake not to end payments to Cohen immediately after determining that he would be of little help.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

  • This line about Jose Jimenez – “He said it was a mistake not to end payments to Cohen immediately after determining that he would be of little help.” – brought the word “clawbacks” to mind. Any chance of that happening? (Rhetorical question …. )

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy